GlassScriptPhysician profile
Melissa S Williams
NPI 1891052163
$3,314.21
in general payments reported to CMS, 2019-2025
18 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $138 · 2021: $19.01 · 2022: $235 · 2023: $703 · 2024: $845 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.42 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $841.38 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $484.56 | 2019-2025 | |
| Janssen Biotech, INC. | $361.98 | 2020-2025 | Tremfya |
| Genzyme Corporation | $286.42 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $269.96 | 2020-2025 | Ilumya |
| Pfizer INC. | $264.39 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $253.41 | 2022-2025 | Sotyktu |
| Ucb, INC. | $147.64 | 2025 | Bimzelx |
| Lilly USA, LLC | $140.16 | 2019-2024 | Taltz, Ebglyss |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Leo Pharma INC. | $57.02 | 2023-2025 | Anzupgo, Adbry |
| Celgene Corporation | $38.12 | 2019 | |
| Organogenesis INC. | $20.63 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $18.88 | 2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $17.27 | 2024 | Zoryve |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $15.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.80 | 2024 | Cyltezo |
| Merck Sharp & Dohme LLC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.